11.28
+0.22(+1.99%)
Currency In USD
| Previous Close | 11.06 |
| Open | 11.01 |
| Day High | 11.51 |
| Day Low | 10.81 |
| 52-Week High | 47.45 |
| 52-Week Low | 6.36 |
| Volume | 1.65M |
| Average Volume | 2.09M |
| Market Cap | 1.28B |
| PE | -3.35 |
| EPS | -3.37 |
| Moving Average 50 Days | 11.12 |
| Moving Average 200 Days | 26.08 |
| Change | 0.22 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $471.97 as of April 29, 2025 at a share price of $11.28. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $1,413.53 as of April 29, 2025 at a share price of $11.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Apr 24, 2025 11:30 AM GMT
- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for late 2025 - WALTHAM, Mass., April 24, 2025 (GL
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
GlobeNewswire Inc.
Apr 15, 2025 11:30 AM GMT
Vikram Ranade, PhD Vikram Ranade, PhD, Chief Business Officer (CBO) of Dyne Therapeutics Ranjan Batra, PhD Ranjan Batra, PhD, Chief Scientific Officer (CSO), of Dyne Therapeutics Oxana Beskrovnaya, PhD Oxana Beskrovnaya, PhD, Chief Innovat
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Apr 14, 2025 8:30 PM GMT
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced